PT - JOURNAL ARTICLE AU - Anurag Sethi AU - Leland Taylor AU - J Graham Ruby AU - Jagadish Venkataraman AU - Elena Sorokin AU - Madeleine Cule AU - Eugene Melamud TI - Calcification of abdominal aorta is a high risk underappreciated cardiovascular disease factor in a general population AID - 10.1101/2020.05.07.20094706 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.07.20094706 4099 - http://medrxiv.org/content/early/2020/10/29/2020.05.07.20094706.short 4100 - http://medrxiv.org/content/early/2020/10/29/2020.05.07.20094706.full AB - Background Abdominal aortic calcification (AAC) is an important contributor to cardiovascular disease, however, prevalence of the pathology, risk factors, and disease outcomes in a general population have not been systematically analyzed.Methods We have analyzed the prevalence of AAC in the UK Biobank cohort using machine learning models across 38,264 whole body dual-energy X-ray absorptiometry (DEXA) scans. We associated severity of calcification across a wide range of physiological parameters, clinical biomarkers, and environmental risk factors (406 in total). We further performed a rare and common variant genetic association study to identify genetic loci relevant to AAC and evaluated the prognostic value of AAC across 174 disease classes.Results We find that AAC is highly prevalent in a general population (>10.4% of the cohort) despite low prevalence of diabetes (2.5%) and CKD (0.5%). Increased level of AAC is a strong prognostic indicator of a wide range of cardiovascular outcomes, including stenosis of precerebral arteries (HR∼1.5), myocardial infarction (HR∼1.36), ischemic heart disease (HR∼1.3), and chronic obstructive pulmonary disease (HR∼1.3). We report four genetic loci associated with AAC, three of which have not been previously reported. Surprisingly, we find that elevated but still within clinically normal levels of serum phosphate, serum calcium, and glycated hemoglobin are linked to increased vascular calcification.Conclusions By our estimate, AAC is an LDL-independent risk factor for cardiovascular outcomes, with risk similar to elevated LDL. Development of anti-calcification therapeutics would complement lipid lowering strategies in reducing CVD burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Calico Life Sciences LLC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank has approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData:This research has been conducted using the UK Biobank Resource.HbA1cglycated hemoglobinGGTgamma glutamyl transferaseApoAapolipoproteinHDLhigh density lipoproteinLDLlow density lipoproteinWBCWhite blood cellMCVmean corpuscular volumeMCHCmean corpuscular haemoglobin concentrationRBCred blood cell, Imm.Reticulocyteimmature reticulocyteIMTintima media thicknessSBPsystolic blood pressurePEFpeak expiratory flowFVCforced vital capacityQUIquantitative ultrasound index, US- ultrasoundBMDbone mineral densityFEV1forced expiratory volume in 1 second